Eckert & Ziegler’s Nine-Month Profit Rises 19% on Radiopharma Demand

Eckert & Ziegler Strahlen- und Medizintechnik AG saw its net profit climb 19% year-over-year to EUR 35.4 million for the first nine months of 2026, driven by continued strong performance in its radiopharmaceuticals business. The results, released November 12th, also show a 2% increase in group revenue over the same period last year, reaching EUR 229 million.

The positive figures spurred a rally in the company’s stock, which rose over 4% on Thursday, reaching a high of EUR 14.57 – the highest level since July. While the stock has recovered somewhat from a low of EUR 12 in early October, it remains nearly 6% down since the end of 2025. However, over a ten-year period, the stock has more than tripled in value.

Underlying the profit growth was a nearly 4% increase in adjusted EBIT, reaching EUR 52.6 million for the first nine months of the year. The company also confirmed its full-year guidance, expecting revenue of around EUR 320 million and adjusted EBIT of approximately EUR 80 million. Management anticipates a positive development in the fourth quarter, alongside sustained demand for radiopharmaceuticals, and forecasts receiving license revenues for the first time this year.

The consistent performance in radiopharmaceuticals, and specifically the successful recovery within the isotope products segment, now positions Eckert & Ziegler to meet its previously outlined annual targets. The 19% profit gain builds on prior momentum, with the company previously projecting an 18.2% year-over-year increase in adjusted EBIT for Q3, driven by rising Lu-177 sales and potential license revenue.